KCNK15 (Potassium Two Pore Domain Channel Subfamily K Member 15), also known as TASK-5 or K2p5.1, is a member of the two-pore domain potassium (K2P) channel family — a class of channels that regulate neuronal excitability, resting membrane potential, and cellular responses to metabolic stress [@kang2015]. Unlike voltage-gated potassium channels that open in response to membrane depolarization, K2P channels produce "background" or "leak" potassium currents that stabilize the resting membrane potential near the potassium equilibrium potential (approximately -90 mV). This leak conductance prevents neurons from becoming hyperexcitable and sets the baseline excitability state that determines how readily a neuron responds to synaptic inputs.
KCNK15 has attracted increasing attention in neurodegenerative disease research due to its documented expression in brain regions central to Alzheimer's disease (AD) and Parkinson's disease (PD) pathology, including the hippocampus and substantia nigra pars compacta. Emerging evidence suggests that KCNK15 dysfunction contributes to neuronal hyperexcitability, impaired stress responses, and synaptic dysfunction that characterize early neurodegeneration. The channel's unique pharmacology — it is modulated by pH, lipids, and volatile anesthetics — also makes it a potential target for neuroprotective therapies.
KCNK15 (Potassium Two Pore Domain Channel Subfamily K Member 15), also known as TASK-5 or K2p5.1, is a member of the two-pore domain potassium (K2P) channel family — a class of channels that regulate neuronal excitability, resting membrane potential, and cellular responses to metabolic stress [@kang2015]. Unlike voltage-gated potassium channels that open in response to membrane depolarization, K2P channels produce "background" or "leak" potassium currents that stabilize the resting membrane potential near the potassium equilibrium potential (approximately -90 mV). This leak conductance prevents neurons from becoming hyperexcitable and sets the baseline excitability state that determines how readily a neuron responds to synaptic inputs.
KCNK15 has attracted increasing attention in neurodegenerative disease research due to its documented expression in brain regions central to Alzheimer's disease (AD) and Parkinson's disease (PD) pathology, including the hippocampus and substantia nigra pars compacta. Emerging evidence suggests that KCNK15 dysfunction contributes to neuronal hyperexcitability, impaired stress responses, and synaptic dysfunction that characterize early neurodegeneration. The channel's unique pharmacology — it is modulated by pH, lipids, and volatile anesthetics — also makes it a potential target for neuroprotective therapies.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">KCNK15 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Potassium Two Pore Domain Channel Subfamily K Member 15</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[KCNK15](/genes/kcnk15)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H5S3](https://www.uniprot.org/uniprot/Q9H5S3)</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>TASK-5, K2p5.1, TASK5</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~41 kDa</td></tr>
<tr><td><strong>Length</strong></td><td>344 amino acids</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma membrane</td></tr>
<tr><td><strong>Protein Family</strong></td><td>K2P (Two-pore domain K⁺) channel family</td></tr>
</table>
</div>
KCNK15 belongs to the K2P channel family, characterized by a unique architecture distinct from all other potassium channel families. Each KCNK15 subunit contains four transmembrane segments (M1–M4) with two pore domains (P1 and P2), giving the family its name [@kang2015]. The channel functions as a homodimer (two subunits) or can form heterodimers with other K2P family members such as TASK-1 (KCNK1) and TASK-3 (KCNK9), creating channels with mixed pharmacological properties.
| Structural Feature | Location | Function |
|-------------------|----------|----------|
| N-terminus | Cytoplasmic | Protein interactions, targeting signals |
| M1 (first transmembrane) | Membrane | Forms outer pore helix |
| P1 (first pore domain) | Between M1-M2 | K⁺ selectivity filter (GYGD motif) |
| M2 (second transmembrane) | Membrane | Inner pore helix, gating |
| M3 (third transmembrane) | Membrane | Structural support, subunit interaction |
| P2 (second pore domain) | Between M3-M4 | K⁺ selectivity, contributes to selectivity |
| M4 (fourth transmembrane) | Membrane | Forms inner gate, gating control |
| C-terminus | Cytoplasmic | Interaction domains, regulatory sites |
The two pore domains contain the signature K⁺ selectivity filter sequence (GYGD motif in P1, modified sequence in P2). These filters allow K⁺ ions to pass with high selectivity over Na⁺ while excluding other ions. The double-pore design means each subunit contributes half of each of the two conduction pathways in the dimer.
KCNK15 exhibits multiple modes of regulation:
KCNK15 channels contribute to the resting membrane potential in neurons by providing a leak potassium conductance [@chen2021]. This "leak" current counteracts depolarizing inputs and stabilizes the neuronal membrane potential near E_K. The equilibrium between leak conductance (KCNK15 and other K2P channels) and excitatory inputs determines whether a neuron is in a "quiet" or "active" state.
In hippocampal and cortical neurons, KCNK15 helps maintain proper neuronal excitability:
K2P channels, including KCNK15, are activated during metabolic stress conditions such as hypoxia and ischemia [@ying2016]. This activation serves as a neuroprotective mechanism:
In the substantia nigra pars compacta, KCNK15 contributes to the unique electrophysiological properties of dopaminergic neurons [@guo2015]:
In the hippocampus, KCNK15 is expressed in CA1 pyramidal neurons and dentate gyrus granule cells:
KCNK15 is implicated in AD through multiple interconnected mechanisms [@chen2021][@ying2016]:
Neuronal Excitability Dysregulation: KCNK15 dysfunction contributes to hippocampal neuron hyperexcitability, a well-documented feature of early AD. Epilepsy and seizure activity are common in AD, and hyperexcitability precedes clinical cognitive decline in many patients. Reduced KCNK15 function would contribute to this hyperexcitability by decreasing leak potassium conductance.
Amyloid-beta Effects on KCNK15: Aβ peptides can directly modulate KCNK15 activity through several mechanisms:
Synaptic Dysfunction: KCNK15 contributes to synaptic plasticity mechanisms by influencing the intracellular signaling cascades activated by synaptic activity. Impaired channel function may contribute to the synaptic loss that underlies cognitive decline in AD.
Therapeutic potential: KCNK15 modulators that selectively increase channel activity could provide neuroprotection by normalizing neuronal excitability and enhancing metabolic stress responses.
In PD, KCNK15 plays critical roles in dopaminergic neuron survival [@guo2015][@buescher2020]:
Dopaminergic Neuron Vulnerability: KCNK15 helps maintain the resting membrane potential in substantia nigra dopamine neurons. Loss of KCNK15 function may contribute to the selective vulnerability of these neurons in PD. Dopaminergic neurons have specific electrophysiological properties — including a relatively depolarized resting potential and calcium channel-dependent pacemaking — that make them dependent on potassium channels like KCNK15 for stability.
Oxidative Stress Response: The channel participates in cellular responses to oxidative stress, a key pathomechanism in PD:
Alpha-synuclein Interaction: Emerging evidence suggests that α-synuclein aggregation may affect KCNK15 channel function:
KCNK15 represents a potential therapeutic target for neurodegenerative diseases [@wang2022]:
| Strategy | Approach | Development Stage | Reference |
|----------|---------|-------------------|-----------|
| Channel openers | Activate KCNK15 to normalize excitability | Research | Wang 2022 |
| pH modulators | Adjust pH sensitivity for enhanced activation | Research | Kang 2015 |
| Lipid mimetics | Enhance lipid-mediated activation | Research | Ying 2016 |
| Gene therapy | Increase KCNK15 expression | Research | Chen 2021 |
Delivery challenges: CNS penetration is necessary for any KCNK15-targeted therapy. Small molecules targeting K2P channels have been developed for other indications (notably as anesthetics and analgesics), providing a foundation for neuroprotective KCNK15 modulators.
Therapeutic window: Excessive KCNK15 activation could lead to neuronal hyperpolarization and reduced excitability below functional thresholds. A therapeutic window exists between physiological and pathophysiological activity.
KCNK15 is expressed in several brain regions relevant to neurodegenerative diseases:
| Brain Region | Expression Level | Functional Relevance |
|--------------|-----------------|---------------------|
| Hippocampus (CA1) | High | Memory circuits, AD vulnerability |
| Dentate gyrus | High | Pattern separation, AD vulnerability |
| Prefrontal cortex | Moderate | Executive function |
| Entorhinal cortex | Moderate | Early AD pathology |
| Substantia nigra | Moderate | PD vulnerability |
| Ventral tegmental area | Moderate | Reward circuitry |
| Thalamus | Low-moderate | Sensory processing |
| Cerebellum | Low | Motor coordination |
| Compound | Effect on KCNK15 | Development Stage | Reference |
|----------|-----------------|-------------------|-----------|
| Halothane | Potentiates (opens channel) | Preclinical (anesthetic) | Wang 2022 |
| Sevoflurane | Potentiates | Preclinical (anesthetic) | Wang 2022 |
| Bupivacaine | Blocks | Preclinical (local anesthetic) | Wang 2022 |
| acidic pH | Activates | Research | Kang 2015 |
| alkaline pH | Inhibits | Research | Kang 2015 |
| Arachidonic acid | Potentiates | Research | Ying 2016 |